<--- Back to Details
First PageDocument Content
Pharmacology / Cyclopropanes / Bristol-Myers Squibb / Gilead Sciences / Non-nucleoside reverse transcriptase inhibitors / Lamivudine / Fixed-dose combination / Efavirenz / Cipla / Chemistry / Organic chemistry / Organofluorides
Pharmacology
Cyclopropanes
Bristol-Myers Squibb
Gilead Sciences
Non-nucleoside reverse transcriptase inhibitors
Lamivudine
Fixed-dose combination
Efavirenz
Cipla
Chemistry
Organic chemistry
Organofluorides

Fast_Track_Internet_as_of_2010[removed]xls

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 270,57 KB

Share Document on Facebook

Similar Documents

A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To

DocID: 1vrK6 - View Document

NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER,

DocID: 1tuCc - View Document

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty)

DocID: 1tut4 - View Document

September 2003 USA Bristol-Myers Squibb Medical Imaging

DocID: 1sKnx - View Document

May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862

DocID: 1sC8T - View Document